Comparative Pharmacology
Head-to-head clinical analysis: ANTEPAR versus BILTRICIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTEPAR versus BILTRICIDE.
ANTEPAR vs BILTRICIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is approximately 0.8-1.5 hours for praziquantel; clinical significance: short half-life necessitates multiple dosing for sustained antiparasitic effect.
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Renal excretion accounts for approximately 80-90% of elimination, primarily as metabolites; biliary/fecal excretion is minor (<10%).
Category C
Category C
Anthelmintic
Anthelmintic